Daunorubicin (RP 13057) HCl - 10mM in DMSO , DNA inhibitor, CAS No.23541-50-6, DNA inhibitor

CAS: 23541-50-6 Cat. No.: D409068 Peso molecular: 563.98 Beilstein Registry Number: 4229221 Número EC: 245-723-4 PubChem CID: 62770

GRADE & PURITY 10mM in DMSO

Synonyms

Daunomycin HCl, Rubidomycin HCl | 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride (1:1), (8S,10S)-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Daunorubicin HCl (Daunomycin, RP 13057, Rubidomycin) inhibits both DNA and RNA synthesis and inhibitsDNAsynthesis withKiof 0.02 μM in a cell-free assay. Daunorubicin is atopoisomerase IIinhibitor that inducesapoptosis.
In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells.

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥95%

Specifications

Sinónimos

Daunomycin HCl, Rubidomycin HCl | 5, 12-Naphthacenedione, 8-acetyl-10-[(3-amino-2, 3, 6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-1-methoxy-, hydrochloride (1:1), (8S, 10S)-

Especificaciones y pureza

10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Daunorubicin HCl (Daunomycin, RP 13057, Rubidomycin) inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Tipo de acción

INHIBITOR

Mecanismo de acción

DNA inhibitor

Nombres e identificadores

• Isómeros SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl
• WGK Alemania: 3
• RTECS: HB7878000
• CAS alternativo: 20830-81-3
• PubChem CID: 62770
• Número ONU: 2811
• Grupo de embalaje: I
• Peso molecular: 563.98
• Beilstein: 4229221

Objetivos asociados (humanos)

S100A4 Tchem Protein S100-A4 (1 Activities)

Discover Target: S100A4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Solubilidad: Solubility (25°C) In vitro
• Rotación específica [α]: 260°
• Punto de fusión (°C): 167 °C

Referencias

1. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo.  (2023)  Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels.  JOURNAL OF CONTROLLED RELEASE,      [PMID:37422124] [10.1016/j.jconrel.2023.07.003]

2. Bo Fu, Can Tao, Nian Chen, Jie-Rou Lin, Ping Zhao.  (2021)  ZnO QD covalently coated, GSH/pH dual-responsive drug delivery system for chemotherapeutic/ionic synergistic therapy.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,      [PMID:] [10.1016/j.jddst.2021.102908]

3. Zhifeng Xu, Peihong Deng, Junhua Li, Li Xu, Siping Tang.  (2017)  Molecularly imprinted fluorescent probe based on FRET for selective and sensitive detection of doxorubicin.  Materials Science and Engineering B-Advanced Functional Solid-State Materials,      [PMID:] [10.1016/j.mseb.2017.02.005]

4. Shule Zhang, Dong Li, Linghong Liu, Qing Shi, Xiuli Ju.  (2024)  Extracellular vesicles derived from HuMSCs alleviate daunorubicin-induced cardiac microvascular injury via miR-186-5p/PARP9/STAT1 signal pathway.  Regenerative Therapy,      [PMID:38327716] [10.1016/j.reth.2024.01.011]